Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620563 · ClinicalTrials.gov registry record · Phase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
NCT05620563 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 147 participants.
The verdict
NCT05620563, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3857210 in participants with Osteoarthritic Pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
Interventions
- DRUG Placebo
- DRUG LY3857210
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2022-11-22 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05620563
The ClinicalTrials.gov registry entry for NCT05620563 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05620563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05620563 about?
NCT05620563 is a clinical study titled "A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain". The main purpose of this study is to evaluate the efficacy and safety of LY3857210 in participants with Osteoarthritic Pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
What is the current status of trial NCT05620563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2022-11-22. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT05620563?
The interventions under investigation include: Placebo (DRUG), LY3857210 (DRUG).
Who is sponsoring clinical trial NCT05620563?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.